Efficacy of Theta Burst Transcranial Magnetic Stimulation for the Treatment of Premenstrual Dysphoric Disorder – An Open Label Pilot Study

Monash University0 个研究点目标入组 30 人开始时间: 2022年6月27日最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•1.Meet the DSM-5 diagnostic criteria for Premenstrual Dysphoric Disorder (PMDD).
•2.Confirmation of PMDD diagnosis using the Carolina Premenstrual Assessment Scoring System (C-PASS) within the past 6 months. This scoring system confirms a PMDD diagnosis using two or more months of daily symptom ratings with the Daily Record of Severity of Problems (DRSP) measurement tool.
•Participants who have had a PMDD diagnosis confirmed with this assessment within the preceding 6 months do not need to repeat the pre-treatment phase of the study
•3.Report of at least a one-year history of regularly experiencing PMDD symptoms.
•4.Women taking the oral contraceptive pill (OCP) or using a hormonal intrauterine device (IUD) are required to have commenced the same OCP or IUD at least 3 months prior to their enrolment, while continuing to meet criteria 1 and 2 above at the time of study consent.
•5.No increase/initiation of new antidepressant(s) in the 4 weeks prior to enrolment.
•6.Demonstrated capacity to give informed consent.

•1.Unable to provide informed consent.
•2.Currently pregnant.
•3.Experiencing an acute medical condition as assessed by the Study PI/Site PI.
•4.Assessed as living with a serious, comorbid mental illness(s) other than Major Depressive Disorder (MDD).
•5.Presenting with clinically-significant risk of suicide.
•6.Assessed as having a concomitant neurological disorder or a history of a seizure disorder.
•7.Assessed as having an active substance or alcohol use disorder.
•8.History of adverse effects to Repetitive Transcranial Magnetic stimulation (rTMS) of clinical significance.

发起方